Pharmacodynamics of natalizumab extended interval dosing in MS

OBJECTIVE: To determine if the concentration and saturation of natalizumab (NTZ) administration at extended interval dosing (EID; every 5–8 weeks) over 18 months is able to be maintained in the range considered adequate to sustain the clinical efficacy of NTZ. METHODS: In a cross-sectional assessmen...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Neurol Neuroimmunol Neuroinflamm
Prif Awduron: Zhovtis Ryerson, Lana, Li, Xiaochun, Goldberg, Judith D., Hoyt, Tamara, Christensen, Angel, Metzger, Ryan R., Kister, Ilya, Foley, John
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Lippincott Williams & Wilkins 2020
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7057061/
https://ncbi.nlm.nih.gov/pubmed/32019876
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/NXI.0000000000000672
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg